Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are the first-line medications for generalized anxiety disorder, backed by the largest body of trial evidence and endorsed by every major treatment guideline. But the landscape of GAD medication is broader than just those two classes, and finding the right fit often involves weighing trade-offs between speed of relief, side effects, and long-term safety that are not obvious from a prescription label.
SSRIs and SNRIs Come Out on Top, but Some Outperform Others
When researchers compare GAD drugs head to head, the differences between individual SSRIs and SNRIs are often small, yet they do exist. A large network meta-analysis published in The Lancet found that duloxetine, pregabalin, venlafaxine, and escitalopram were more effective than placebo while maintaining relatively good acceptability.1The Lancet. Comparative efficacy and acceptability of pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis A separate network meta-analysis found duloxetine and escitalopram showed the best balance of efficacy, while vortioxetine had better tolerability but weaker anxiety reduction.2PubMed. Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: A network meta-analysis Sertraline, fluoxetine, and buspirone also showed efficacy, though the evidence base for each was smaller.3The Lancet. Comparative efficacy and acceptability of pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis
In practical terms, this means your prescriber will often start with escitalopram, sertraline, duloxetine, or venlafaxine. The choice between an SSRI and an SNRI often comes down to your other symptoms. If you also deal with chronic pain or fibromyalgia, duloxetine may pull double duty. If you have few comorbidities and want the gentlest introduction, escitalopram tends to have a clean side-effect profile. None of these work immediately. You should expect at least two to four weeks before anxiety levels start to drop meaningfully, and sometimes six to eight weeks for the full effect.
Buspirone as a Non-Antidepressant Alternative
Buspirone occupies a curious niche. It is FDA-approved for GAD, is not related to benzodiazepines or barbiturates, and carries no risk of physical dependence. It works through partial activation of a specific serotonin receptor subtype, though the exact way this translates into reduced anxiety is still not fully understood.4Psychopharmacology Institute. Buspirone Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects Like SSRIs, it takes two to four weeks to begin working, so it is not useful for fast relief.
Buspirone lands as a second-line option in most guidelines.5PubMed Central. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review Prescribers sometimes add it alongside an SSRI if the SSRI alone isn’t cutting it, or use it as a standalone when antidepressants cause intolerable sexual side effects or emotional blunting. The main complaint patients report is that the effect feels subtle. People who have previously taken benzodiazepines and expect a noticeable wave of calm often find buspirone underwhelming, even when objective anxiety scores improve.
Pregabalin and Its Unusual Place in Treatment
Pregabalin works through a mechanism unrelated to serotonin. It binds to a subunit on certain calcium channels in overexcited neurons, which reduces the release of excitatory brain chemicals like glutamate.6PubMed Central. Pregabalin for the treatment of generalized anxiety disorder: an update Trial data show it works as well as benzodiazepines and venlafaxine for GAD, with some evidence it kicks in faster than SSRIs.7PubMed. Pregabalin: From molecule to medicine It only acts on neurons that are in a hyperactive state, leaving normally functioning ones alone, which may explain why sedation tends to be milder than with benzodiazepines.8PubMed. Pregabalin: From molecule to medicine
Here is the catch: pregabalin is approved for GAD in Europe but not in the United States, where the FDA has only cleared it for nerve pain, fibromyalgia, and seizures. American prescribers can still use it off-label, but insurance coverage varies, and it was reclassified as a Schedule V controlled substance in the U.S. in 2019 due to some reports of misuse. If you live in Europe, you may be offered pregabalin alongside or instead of an SSRI. If you live in the U.S., it is more likely to appear as an add-on when standard treatments have not worked.
The Benzodiazepine Question
Benzodiazepines like alprazolam, lorazepam, and clonazepam can provide rapid relief from acute anxiety, sometimes within thirty minutes.9PubMed Central. Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives That speed is exactly why they remain widely prescribed for GAD despite being listed as second-line in guidelines. The problem is everything else: physical dependence develops with regular use, withdrawal can be severe, cognitive dulling accumulates, and fall risk increases in older adults. They are linked to adverse effects whether used long-term, short-term, or as needed.10PubMed Central. Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives
Most guidelines now recommend benzodiazepines only as a bridge during the first weeks of SSRI or SNRI treatment, before the antidepressant reaches its full effect, and only for a defined period. The reality in clinical practice is messier. Many patients end up taking benzodiazepines for months or years, sometimes because tapering off is difficult, sometimes because nothing else works as quickly. If you are currently on a benzodiazepine and want to stop, the standard advice is to taper gradually under medical supervision rather than quitting abruptly.
Beta-Blockers and Hydroxyzine for Physical Symptoms
Propranolol and other beta-blockers are sometimes prescribed for anxiety, though their evidence base for GAD specifically is thin. Their benefit appears limited to the physical symptoms of anxiety, like racing heart, trembling, and sweating, likely because they act on receptors outside the brain rather than altering central nervous system chemistry.11Stress Medicine. Beta‐blockers in anxiety For someone whose GAD manifests mainly as rumination and dread, a beta-blocker probably won’t help much. For someone whose anxiety spikes produce pounding heartbeats and shaking hands, it can take the edge off the body’s response. One recent review flagged propranolol’s limited efficacy for anxiety overall and noted that less lipophilic beta-blockers might offer a better safety profile with similar results for somatic symptoms.12British Journal of General Practice. Propranolol in anxiety: poor evidence for efficacy and toxicity in overdose
Hydroxyzine, an antihistamine, is another option sometimes used on an as-needed basis. A three-month double-blind trial found it significantly outperformed placebo on anxiety scores and response rates.13PubMed. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study It works quickly, within an hour or two, and carries no dependence risk. The trade-off is drowsiness. Some people find the sedation useful at night and intolerable during the day. Hydroxyzine fills a gap for patients who need occasional fast-acting relief but want to avoid benzodiazepines.
When the First Medication Doesn’t Work
Roughly a third to a half of GAD patients do not respond adequately to their first medication trial. The clinical term for this is treatment-resistant GAD, and the evidence base for what to do next is considerably thinner than the evidence for first-line treatment. A review of available literature found two drug classes with the most data supporting their use as add-on therapies: GABA-related agents (including pregabalin and benzodiazepines) and atypical antipsychotics.14PubMed Central. Management of treatment-resistant generalized anxiety disorder
Among the antipsychotics, low-dose quetiapine has the most data. One randomized trial found that adding roughly 50 mg per day of quetiapine to an SSRI produced significantly greater improvement in anxiety scores compared to SSRI plus placebo in patients who had not responded to the SSRI alone.15International Clinical Psychopharmacology. Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study The word “antipsychotic” can be alarming when your diagnosis is anxiety, not psychosis, but these drugs are used at much lower doses for GAD than for conditions like schizophrenia. Still, they carry metabolic side effects like weight gain and blood sugar changes, so they are not prescribed casually.
Does Combining Medication with Therapy Help?
Most clinicians will tell you that medication plus cognitive behavioral therapy beats medication alone. The research backing that intuition for GAD specifically is surprisingly mixed. One controlled study looked at combining venlafaxine with cognitive therapy and found no additional benefit on primary outcome measures compared to venlafaxine alone.16PubMed Central. Combined medication and cognitive therapy for generalized anxiety disorder That does not mean therapy is useless for GAD. It means that once a medication is working, stacking formal CBT on top may not produce measurably larger anxiety-score improvements in the short term. Therapy likely helps in ways that standardized anxiety questionnaires don’t fully capture: better coping strategies, fewer relapses after stopping medication, and a sense of agency over your own thought patterns.
If you are someone who prefers not to take medication long-term, therapy may be particularly valuable as a relapse prevention tool when you eventually taper off.
GAD Medication in Children and Adolescents
SSRIs and SNRIs are also the go-to medications for children and teenagers with GAD, but the evidence base is smaller. A systematic review of five trials involving nearly 1,200 young patients found that these drugs did reduce anxiety, with the number needed to treat ranging from about 3 to 9, meaning between three and nine children needed to be treated for one to benefit beyond what placebo would produce.17PubMed Central. Pharmacotherapy for Pediatric Generalized Anxiety Disorder: A Systematic Evaluation of Efficacy, Safety and Tolerability Side effects tended to be mild and rarely led to stopping the medication.
Venlafaxine extended-release has been specifically studied in two pediatric trials. A pooled analysis showed greater anxiety reduction in the venlafaxine group compared to placebo, and about 69% of children on the drug were rated as improved versus 48% on placebo.18PubMed. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials However, the venlafaxine group also showed measurable changes in height, weight, blood pressure, pulse, and cholesterol, which means close monitoring is essential in growing kids.19PubMed. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials Benzodiazepines are generally avoided in this age group because of cognitive effects and the developmental unknowns.
GAD Medication in Older Adults
Treating anxiety in older adults is complicated by polypharmacy and shifting metabolism. SSRIs remain first-line, but the specific SSRI matters more than it does in younger adults. Some SSRIs are strong inhibitors of liver enzymes responsible for processing other drugs, which can cause dangerous interactions in someone taking five or six medications. Those SSRIs with milder effects on liver metabolism are preferred.20PubMed Central. Pharmacological Management of Anxiety Disorders in the Elderly Mirtazapine and vortioxetine are also considered safe options in this population.
Benzodiazepines and beta-blockers should generally be avoided in older adults due to fall risk and cognitive impairment.21PubMed Central. Pharmacological Management of Anxiety Disorders in the Elderly Antipsychotics carry a black-box warning for increased mortality in elderly patients with dementia, which limits their use even as augmentation strategies. Older tricyclic antidepressants and MAOIs can be effective but carry side-effect and safety profiles that make them poor choices in late life.22PubMed Central. Pharmacological Management of Anxiety Disorders in the Elderly The upshot is that elderly patients typically have fewer safe medication options and may need more cautious dose escalation.
Pregnancy, Breastfeeding, and the Risk-Benefit Tightrope
SSRIs are the most studied psychiatric medications during pregnancy, but “most studied” is relative. The evidence is criticized for inconsistent study designs and conflicting findings.23PubMed Central. Antidepressants, anxiolytics, and hypnotics in pregnancy and lactation Psychotropic drugs cross the placenta, and the effects on the developing fetus remain incompletely understood.24PubMed. Treatment of anxiety during pregnancy: effects of psychotropic drug treatment on the developing fetus
Current guidance suggests avoiding medications during the first trimester when possible and using the lowest effective dose throughout pregnancy. In severe cases where discontinuation risks relapse, treatment continues with an individualized risk-benefit assessment.25PubMed. Psychotropic drugs in pregnancy and lactation The core tension is real: untreated severe anxiety during pregnancy carries its own risks, including elevated stress hormones, poor prenatal care, and disrupted bonding. Stopping medication that was keeping you stable can sometimes be more harmful than continuing it. This is one area where a conversation with your prescriber and an obstetrician matters more than any general advice an article can offer.26PubMed Central. Antidepressants, anxiolytics, and hypnotics in pregnancy and lactation
The Placebo Problem in Anxiety Trials
One reason GAD medications often look only modestly better than placebo in trials is that the placebo response in anxiety research is unusually large. A three-level meta-analysis found that the high placebo response associated with SSRIs and SNRIs can obscure the real benefit of these drugs, since clinicians in practice cannot distinguish between improvement caused by the medication and improvement caused by the expectation of treatment.27PubMed Central. Placebo response in trials with patients with anxiety, obsessive-compulsive and stress disorders across the lifespan
This does not mean the medications are just placebos in disguise. It means that the therapeutic context itself, seeing a professional regularly, being monitored, having a structured treatment plan, likely contributes to improvement. When you read that an anxiety drug beat placebo by only a few points on a rating scale, keep in mind that both groups improved. The drug pushed improvement further, but the difference looks modest because the placebo group did surprisingly well. This pattern is one reason why researchers have had a hard time getting newer GAD drugs through clinical trials: the bar for beating placebo is higher than it appears.
Pharmacogenomics and Choosing the Right Drug Faster
One of the most frustrating aspects of GAD treatment is the trial-and-error approach. You start a medication, wait six weeks, decide whether it is working, and if not, try another. Pharmacogenomic testing aims to shorten that cycle by identifying genetic variants that affect how your body metabolizes specific drugs. A prospective study of outpatient anxiety patients found that those whose prescriptions were guided by genetic testing had fewer psychiatric side effects, no hospitalizations (compared to hospitalizations in the non-tested group), and required fewer additional medications overall.28Nature Mental Health. Clinical implementation of pre-emptive pharmacogenomics in patients with anxiety disorders
The testing focuses primarily on genes that encode liver enzymes responsible for breaking down antidepressants. If you are a rapid metabolizer, a standard dose might clear your system too fast to be effective. If you are a poor metabolizer, the same dose might build up and cause side effects. The test does not predict whether anxiety will respond to a given drug; it predicts whether your body will handle the drug normally. Insurance coverage for these tests varies, and they are not yet routine in most practices, but they are becoming more accessible.
How GAD Medications Affect Sleep
Sleep disruption is one of the hallmark features of GAD, and medications interact with sleep architecture in different ways. Pregabalin stands out here: it has been shown to increase deep restorative sleep compared to placebo. In contrast, alprazolam, a benzodiazepine, significantly reduced that same deep-sleep stage.29International Journal of Neuropsychopharmacology. Effects of pregabalin on sleep in generalized anxiety disorder This is an underappreciated distinction. Benzodiazepines can help you fall asleep, but the quality of sleep they produce is not the same as natural sleep. Patients who switch from a benzodiazepine to pregabalin sometimes report feeling more rested even if total sleep time stays the same.
SSRIs and SNRIs have variable effects on sleep. Some people find that escitalopram or sertraline causes initial insomnia that fades after a few weeks. Others experience more vivid dreams. Mirtazapine is sedating at low doses and is sometimes prescribed specifically for anxious patients who cannot sleep, though it carries a risk of weight gain. If sleep problems are a major part of your GAD picture, it is worth flagging that specifically so your prescriber can factor it into the drug choice.
Experimental and Pipeline Medications
Researchers are exploring several new approaches that go beyond serotonin-based drugs. Investigational treatments for GAD include drugs that target the brain’s glutamate system, modulators of the stress-hormone pathway involving corticotropin-releasing factor, and new types of GABA-active compounds that aim to reproduce the fast calming effect of benzodiazepines without the dependence risk.30PubMed. Novel investigational therapeutics for generalized anxiety disorder (GAD) None of these have reached the market yet, and as the placebo-response issue described earlier suggests, getting new anxiety drugs through trials is a steep climb. But the variety of mechanisms under investigation reflects a recognition that current treatments, while helpful for many, leave too many patients partially treated or dealing with side effects they shouldn’t have to accept.